Host-Directed TB Therapy: New Approaches (UH2/UH3)

Post Date

November 12th 2014

Application Due Date

March 25th 2015

Funding Opportunity Number

RFA-AI-14-058

CFDA Number(s)

93.855
93.856

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $2900000

• Award Range:

  $None - $None

Grant Description

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for support of preclinical evaluation, planning for and conduct of proof-of-concept clinical studies for Mycobacterium tuberculosis (TB) treatment that will be applicable in the context of HIV co-infection using host-directed agents already approved for clinical use or in late-stage clinical trials for other conditions. Host-directed therapies (HDT) for TB that may also have activity against HIV, either directly or by enhancing immunologic reactions, are of particular interest. Funds from the NIH will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 award (up to two years) will support the development of critical preclinical data, development of study partnerships, and development of the proof-of-concept (POC) trial protocol and all supporting plans and documentation. Once UH2 pre-clinical and clinical milestones have been met, the UH3 award (up to 3 years) may be made to support the planned POC clinical trial.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-058.html